Skip to content
10-K

Annual Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-25-002237

← back to feed
Filed
Dec 1, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Nov 26, 2025 207.03M sh
Stock Issued FY 2023 · Jan 31, 2023 510K sh
Capex FY 2023 · Jan 31, 2023 $0
Capex FY 2023 · Jan 31, 2022 $73K
Shares Diluted FY 2023 · Jan 31, 2022 205.98M sh
Operating Cash Flow restated FY 2023 · Jan 31, 2022 −$269.63K
Current Liabilities restated FY 2023 · Jan 31, 2022 $1.74M
Total Liabilities FY 2023 · Jan 31, 2022 $2.03M
Current Assets FY 2023 · Jan 31, 2022 $3.06M
Total Assets FY 2023 · Jan 31, 2022 $3.6M
Eps Diluted FY 2023 · Jan 31, 2022 $0.00
Sga Expense restated FY 2023 · Jan 31, 2022 $941.34K
Net Income restated FY 2023 · Jan 31, 2022 $909.56K
Operating Income restated FY 2023 · Jan 31, 2022 $1.13M
Gross Profit FY 2023 · Jan 31, 2022 $2.07M
Cost Of Revenue FY 2023 · Jan 31, 2022 $3.55M
Revenue FY 2023 · Jan 31, 2022 $5.61M
Stockholders Equity FY 2023 · Jan 31, 2021 $96.36K